Revolution Medicines (RVMD) Financials

$39.98 +0.90 (+2.30%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$38.40 -1.58 (-3.95%)

As of 05/30/2025 05:59 PM Eastern

Annual Income Statements for Revolution Medicines

This table shows Revolution Medicines' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Net Income / (Loss) Attributable to Common Shareholders	-600	-436	-249	-187	-110	-62	-49
Consolidated Net Income / (Loss)	-600	-436	-249	-187	-108	-48	-42
Net Income / (Loss) Continuing Operations	-600	-436	-249	-187	-108	-48	-42
Total Pre-Tax Income	-601	-440	-249	-187	-109	-52	-42
Total Operating Income	-690	-487	-258	-188	-111	-54	-40
Total Gross Profit	0.00	12	35	29	43	50	20
Total Revenue	0.00	12	35	29	43	50	20
Operating Revenue	0.00	12	35	29	43	50	20
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	690	499	294	217	154	104	60
Selling, General & Admin Expense	97	76	41	30	21	12	9.41
Research & Development Expense	592	423	253	187	132	92	51
Total Other Income / (Expense), net	89	47	9.15	0.92	2.17	2.08	-1.46
Interest & Investment Income	87	47	9.15	0.93	2.24	2.19	0.78
Other Income / (Expense), net	-2.53	-0.19	0.00	-0.01	-	-	-2.12
Income Tax Expense	-0.75	-3.52	-0.42	0.00	-0.37	-4.37	0.00
Basic Earnings per Share	($3.58)	($3.86)	($3.08)	($2.57)	($2.01)	($22.33)	($21.24)
Weighted Average Basic Shares Outstanding	167.74M	113.15M	80.63M	72.81M	54.87M	2.77M	2.30M
Diluted Earnings per Share	($3.58)	($3.86)	($3.08)	($2.57)	($2.01)	($22.33)	($21.24)
Weighted Average Diluted Shares Outstanding	167.74M	113.15M	80.63M	72.81M	54.87M	2.77M	2.30M
Weighted Average Basic & Diluted Shares Outstanding	185.91M	164.69M	90.49M	72.81M	54.87M	2.77M	2.30M

This table shows Revolution Medicines' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-213	-195	-156	-133	-116	-162	-108	-98	-68	-53	-73
Consolidated Net Income / (Loss)	-213	-195	-156	-133	-116	-162	-108	-98	-68	-53	-73
Net Income / (Loss) Continuing Operations	-213	-195	-156	-133	-116	-162	-108	-98	-68	-53	-73
Total Pre-Tax Income	-213	-195	-156	-133	-116	-161	-112	-98	-68	-53	-74
Total Operating Income	-241	-216	-176	-157	-141	-180	-123	-109	-75	-58	-77
Total Gross Profit	0.00	-	0.00	0.00	0.00	0.74	0.00	3.82	7.01	14	3.36
Total Revenue	0.00	-	0.00	0.00	0.00	0.74	0.00	3.82	7.01	14	3.36
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	241	216	176	157	141	181	123	113	82	71	80
Selling, General & Admin Expense	35	29	24	22	23	32	16	15	13	9.74	10
Research & Development Expense	206	188	152	135	118	148	108	98	69	62	69
Total Other Income / (Expense), net	27	21	19	23	25	19	11	10	7.06	4.51	2.91
Interest & Investment Income	25	21	20	21	24	19	11	10	7.06	4.51	2.91
Other Income / (Expense), net	2.43	-5.83	0.28	1.92	1.10	-0.19	0.00	0.00	0.00	-	-
Basic Earnings per Share	($1.13)	($1.13)	($0.94)	($0.81)	($0.70)	($1.23)	($0.99)	($0.92)	($0.72)	($0.57)	($0.87)
Weighted Average Basic Shares Outstanding	188.15M	167.74M	166.84M	165.14M	164.73M	113.15M	109.23M	106.88M	94.83M	80.63M	84.69M
Diluted Earnings per Share	($1.13)	($1.13)	($0.94)	($0.81)	($0.70)	($1.23)	($0.99)	($0.92)	($0.72)	($0.57)	($0.87)
Weighted Average Diluted Shares Outstanding	188.15M	167.74M	166.84M	165.14M	164.73M	113.15M	109.23M	106.88M	94.83M	80.63M	84.69M
Weighted Average Basic & Diluted Shares Outstanding	186.27M	185.91M	168.22M	167.04M	164.99M	164.69M	109.56M	-	109.17M	90.49M	88.79M

This table details how cash moves in and out of Revolution Medicines' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Net Change in Cash & Equivalents	-152	536	53	4.88	88	-53	61
Net Cash From Operating Activities	-557	-351	-224	-147	-100	-50	1.21
Net Cash From Continuing Operating Activities	-557	-356	-224	-147	-100	-50	1.21
Net Income / (Loss) Continuing Operations	-600	-436	-249	-187	-108	-48	-42
Consolidated Net Income / (Loss)	-600	-436	-249	-187	-108	-48	-42
Depreciation Expense	6.56	-	3.97	3.08	2.61	2.27	1.57
Amortization Expense	-39	-18	2.61	7.26	4.90	0.62	0.20
Non-Cash Adjustments To Reconcile Net Income	75	62	31	21	8.89	3.98	3.18
Changes in Operating Assets and Liabilities, net	0.65	37	-13	8.72	-8.30	-8.83	38
Net Cash From Investing Activities	-554	-343	-24	-142	-234	-102	-1.34
Net Cash From Continuing Investing Activities	-554	-343	-24	-142	-234	-102	-1.34
Purchase of Property, Plant & Equipment	-10	-7.73	-11	-6.53	-2.93	-2.59	-1.50
Purchase of Investments	-2,137	-1,059	-613	-671	-544	-172	0.00
Sale and/or Maturity of Investments	1,593	724	599	536	313	67	0.00
Net Cash From Financing Activities	959	1,229	301	294	423	99	61
Net Cash From Continuing Financing Activities	959	1,229	301	294	423	99	61
Issuance of Common Equity	959	392	301	295	423	0.28	0.42
Other Financing Activities, net	0.28	837	0.04	-0.42	0.00	-1.65	0.13

This table details how cash moves in and out of Revolution Medicines' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-210	343	-75	-13	-408	338	-22	-46	266	-18	73
Net Cash From Operating Activities	-194	-138	-130	-128	-161	-121	-100	-67	-62	-62	-52
Net Cash From Continuing Operating Activities	-194	-138	-130	-128	-161	-126	-100	-67	-62	-62	-52
Net Income / (Loss) Continuing Operations	-213	-195	-156	-133	-116	-162	-108	-98	-68	-57	-73
Consolidated Net Income / (Loss)	-213	-195	-156	-133	-116	-162	-108	-98	-68	-57	-73
Depreciation Expense	1.69	1.74	1.64	1.64	1.54	-	1.27	1.22	1.21	1.15	0.99
Amortization Expense	-7.79	-7.17	-8.36	-9.75	-14	-7.12	-4.27	-4.30	-2.25	-1.14	0.28
Non-Cash Adjustments To Reconcile Net Income	23	19	22	18	15	26	14	13	9.70	8.32	8.14
Changes in Operating Assets and Liabilities, net	2.44	42	10	-4.74	-47	21	-2.73	21	-2.95	-14	12
Net Cash From Investing Activities	-16	-393	-21	108	-248	-380	77	-44	4.00	-7.10	-123
Net Cash From Continuing Investing Activities	-16	-393	-21	108	-248	-380	77	-44	4.00	-7.10	-123
Purchase of Property, Plant & Equipment	-3.27	-1.22	-3.52	-2.40	-3.17	-2.32	-2.54	-1.12	-1.76	-2.88	-3.53
Purchase of Investments	-510	-695	-365	-375	-702	-520	-170	-176	-193	-160	-213
Sale and/or Maturity of Investments	497	304	347	485	457	142	250	134	199	156	93
Net Cash From Financing Activities	0.87	874	77	7.50	0.81	839	1.01	65	324	51	248
Net Cash From Continuing Financing Activities	0.87	874	77	7.50	0.81	839	1.01	65	324	51	248
Issuance of Common Equity	0.89	874	77	7.50	0.81	2.55	1.01	65	324	51	248
Other Financing Activities, net	-0.02	-	-	-	-	-	-	-	-	-	-

This table presents Revolution Medicines' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Total Assets	2,558	2,062	812	738	567	221
Total Current Assets	2,328	1,879	660	590	454	134
Cash & Equivalents	543	696	161	108	104	17
Short-Term Investments	1,746	1,157	484	469	336	106
Accounts Receivable	0.00	1.25	4.67	5.93	6.39	8.74
Prepaid Expenses	38	25	11	6.79	6.99	2.49
Plant, Property, & Equipment, net	24	23	19	12	8.90	7.15
Total Noncurrent Assets	206	160	133	137	104	79
Goodwill	15	15	15	15	15	15
Intangible Assets	57	58	59	60	61	62
Other Noncurrent Operating Assets	135	87	60	62	29	2.78
Total Liabilities & Shareholders' Equity	2,558	2,062	812	738	567	221
Total Liabilities	293	236	127	135	93	68
Total Current Liabilities	164	144	62	60	47	43
Accounts Payable	54	62	21	14	13	11
Accrued Expenses	97	75	29	28	19	15
Other Current Liabilities	13	7.37	6.77	6.21	3.67	0.00
Total Noncurrent Liabilities	129	92	65	75	46	25
Noncurrent Deferred & Payable Income Tax Liabilities	2.35	3.12	7.03	7.44	7.44	7.82
Other Noncurrent Operating Liabilities	127	89	58	61	30	0.66
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	2,265	1,826	685	603	475	-153
Total Preferred & Common Equity	2,265	1,826	685	603	475	-153
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	2,265	1,826	685	603	475	-153
Common Stock	4,002	2,963	1,388	1,056	740	4.74
Retained Earnings	-1,738	-1,138	-701	-453	-266	-157
Accumulated Other Comprehensive Income / (Loss)	1.32	0.54	-1.78	-0.38	0.12	0.07

This table presents Revolution Medicines' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	9/30/2022
Total Assets	2,365	1,763	1,808	1,908	984	1,074	826
Total Current Assets	2,135	1,579	1,625	1,729	824	922	675
Cash & Equivalents	334	201	276	288	358	380	179
Short-Term Investments	1,769	1,348	1,315	1,415	455	529	476
Accounts Receivable	0.00	0.00	0.00	0.00	0.31	2.51	4.94
Prepaid Expenses	32	30	34	26	11	10	15
Plant, Property, & Equipment, net	27	25	25	24	20	20	18
Total Noncurrent Assets	204	159	158	155	139	132	133
Goodwill	15	15	15	15	15	15	15
Intangible Assets	56	57	57	57	58	58	59
Other Noncurrent Operating Assets	133	88	87	83	67	59	59
Total Liabilities & Shareholders' Equity	2,365	1,763	1,808	1,908	984	1,074	826
Total Liabilities	287	197	190	183	147	143	144
Total Current Liabilities	159	111	105	94	86	78	73
Accounts Payable	48	24	29	32	30	30	24
Accrued Expenses	98	78	68	53	50	43	32
Other Current Liabilities	13	8.40	8.33	8.17	5.76	5.72	7.02
Total Noncurrent Liabilities	129	86	84	89	61	65	71
Noncurrent Deferred & Payable Income Tax Liabilities	2.35	3.12	3.12	3.12	3.16	7.03	7.15
Other Noncurrent Operating Liabilities	126	83	81	86	58	58	59
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	2,078	1,566	1,619	1,725	837	931	681
Total Preferred & Common Equity	2,078	1,566	1,619	1,725	837	931	681
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	2,078	1,566	1,619	1,725	837	931	681
Common Stock	4,028	3,106	3,008	2,980	1,815	1,800	1,329
Retained Earnings	-1,951	-1,543	-1,387	-1,254	-976	-868	-645
Accumulated Other Comprehensive Income / (Loss)	1.71	3.81	-1.86	-1.20	-0.87	-1.25	-2.42

This table displays calculated financial ratios and metrics derived from Revolution Medicines' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Growth Metrics	-	-	-	-	-	-	-
Revenue Growth	-100.00%	-67.27%	20.38%	-31.62%	-14.10%	148.16%	0.00%
EBITDA Growth	-43.44%	-100.76%	-41.66%	-72.19%	-101.42%	-25.91%	0.00%
EBIT Growth	-42.00%	-88.70%	-37.37%	-69.85%	-104.54%	-27.49%	0.00%
NOPAT Growth	-41.53%	-88.63%	-37.38%	-69.84%	-104.54%	-34.20%	0.00%
Net Income Growth	-37.52%	-75.46%	-32.93%	-72.98%	-126.92%	-14.06%	0.00%
EPS Growth	7.25%	-25.32%	-19.84%	-27.86%	91.00%	-5.13%	0.00%
Operating Cash Flow Growth	-59.01%	-56.23%	-52.47%	-47.09%	-101.68%	-4,190.35%	0.00%
Free Cash Flow Firm Growth	-77.11%	-40.15%	-58.73%	-50.88%	-20.67%	0.00%	0.00%
Invested Capital Growth	9.96%	-166.50%	57.74%	-24.82%	13.96%	0.00%	0.00%
Revenue Q/Q Growth	-100.00%	-52.98%	13.95%	2.47%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-6.09%	-35.88%	-3.11%	-11.40%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	-6.46%	-33.61%	-1.84%	-11.14%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	-5.56%	-33.56%	-1.84%	-11.13%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	-5.83%	-33.14%	-0.10%	-10.95%	0.00%	0.00%	0.00%
EPS Q/Q Growth	2.72%	-20.63%	4.64%	-14.73%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-3.28%	-20.14%	-11.16%	-10.70%	-15.44%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	-7.90%	-8.23%	-12.12%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	-243.23%	-210.30%	52.41%	-13.66%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-
Gross Margin	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	0.00%	-4,363.65%	-711.42%	-604.55%	-240.06%	-102.37%	-201.77%
Operating Margin	0.00%	-4,207.12%	-730.01%	-639.70%	-257.54%	-108.15%	-200.00%
EBIT Margin	0.00%	-4,208.75%	-730.01%	-639.74%	-257.54%	-108.15%	-210.51%
Profit (Net Income) Margin	0.00%	-3,768.28%	-702.95%	-636.58%	-251.63%	-95.25%	-207.24%
Tax Burden Percent	99.87%	99.20%	99.83%	100.00%	99.66%	91.60%	100.00%
Interest Burden Percent	86.82%	90.26%	96.46%	99.51%	98.04%	96.15%	98.44%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-5,058.28%	-549.87%	-442.75%	-243.24%	-254.45%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-5,050.65%	-538.76%	-431.85%	-232.36%	-238.52%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	5,023.53%	511.25%	408.02%	208.76%	191.96%	0.00%
Return on Equity (ROE)	-29.33%	-34.75%	-38.63%	-34.74%	-34.49%	-62.50%	0.00%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-594.68%	-414.42%	-256.30%	-454.45%	0.00%
Operating Return on Assets (OROA)	0.00%	-33.92%	-33.33%	-28.81%	-28.10%	-24.54%	0.00%
Return on Assets (ROA)	0.00%	-30.37%	-32.09%	-28.66%	-27.45%	-21.61%	0.00%
Return on Common Equity (ROCE)	-29.33%	-34.75%	-38.63%	-34.74%	-17.71%	62.51%	0.00%
Return on Equity Simple (ROE_SIMPLE)	-26.49%	-23.89%	-36.30%	-31.05%	-22.79%	31.24%	0.00%
Net Operating Profit after Tax (NOPAT)	-483	-341	-181	-132	-77	-38	-28
NOPAT Margin	0.00%	-2,944.99%	-511.01%	-447.79%	-180.28%	-75.71%	-140.00%
Net Nonoperating Expense Percent (NNEP)	-5.67%	-7.63%	-11.11%	-10.90%	-10.89%	-15.93%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	-21.31%	-18.67%	-26.39%	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	653.03%	114.71%	103.61%	49.85%	24.79%	46.67%
R&D to Revenue	0.00%	3,654.09%	715.30%	636.09%	307.68%	183.36%	253.33%
Operating Expenses to Revenue	0.00%	4,307.12%	830.01%	739.70%	357.54%	208.15%	300.00%
Earnings before Interest and Taxes (EBIT)	-692	-487	-258	-188	-111	-54	-42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-725	-505	-252	-178	-103	-51	-41
Valuation Ratios	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.25	1.72	3.09	3.08	5.54	0.00	0.00
Price to Tangible Book Value (P/TBV)	3.35	1.79	3.46	3.51	6.58	0.00	0.00
Price to Revenue (P/Rev)	0.00	271.36	59.78	63.11	61.14	3.00	7.44
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	36.53	50.08	64.45	11.16	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	111.34	41.55	43.47	50.89	6.64	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.01	-0.99	-0.95	-0.94	-0.90	-0.80	0.00
Leverage Ratio	1.13	1.14	1.20	1.21	1.26	1.45	0.00
Compound Leverage Factor	0.98	1.03	1.16	1.21	1.23	1.39	0.00
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	200.03%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	-100.03%	0.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	14.23	7.47	8.68	7.42	16.64	0.24	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	48.65%	200.03%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-
Current Ratio	14.20	13.06	10.65	9.77	9.63	3.11	0.00
Quick Ratio	13.97	12.89	10.48	9.66	9.48	3.05	0.00
Cash Flow Metrics	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-485	-274	-196	-123	-82	-68	0.00
Operating Cash Flow to CapEx	-5,407.80%	-4,535.80%	-2,074.71%	-2,254.60%	-3,411.66%	-2,073.38%	80.92%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	-1,149.94	-638.31	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	-1,409.35	-468.08	10.46
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	-1,450.66	-490.65	-2.47
Efficiency Ratios	-	-	-	-	-	-	-
Asset Turnover	0.00	0.01	0.05	0.05	0.11	0.23	0.00
Accounts Receivable Turnover	0.00	3.91	6.67	4.77	5.68	5.73	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.56	2.34	2.87	5.36	7.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	93.41	54.69	76.51	64.24	63.73	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	93.41	54.69	76.51	64.24	63.73	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-
Invested Capital	-24	-27	40	26	34	30	0.00
Invested Capital Turnover	0.00	1.72	1.08	0.99	1.35	3.36	0.00
Increase / (Decrease) in Invested Capital	2.67	-67	15	-8.42	4.16	30	0.00
Enterprise Value (EV)	5,069	1,289	1,470	1,278	2,187	332	0.00
Market Capitalization	7,358	3,142	2,115	1,855	2,628	150	150
Book Value per Share	$13.47	$16.67	$7.72	$8.18	$7.15	($55.03)	$0.00
Tangible Book Value per Share	$13.04	$16.01	$6.89	$7.17	$6.01	($82.66)	$0.00
Total Capital	2,265	1,826	685	603	475	153	0.00
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-2,289	-1,853	-645	-577	-441	-123	0.00
Capital Expenditures (CapEx)	10	7.73	11	6.53	2.93	2.39	1.50
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-126	-118	-47	-48	-34	-32	0.00
Debt-free Net Working Capital (DFNWC)	2,164	1,735	598	529	407	91	0.00
Net Working Capital (NWC)	2,164	1,735	598	529	407	91	0.00
Net Nonoperating Expense (NNE)	117	95	68	55	31	9.78	14
Net Nonoperating Obligations (NNO)	-2,289	-1,853	-645	-577	-441	-123	0.00
Total Depreciation and Amortization (D&A)	-33	-18	6.58	10	7.51	2.89	1.76
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-1,014.90%	-132.11%	-162.07%	-78.62%	-63.61%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	14,986.44%	1,690.79%	1,801.37%	946.76%	181.71%	0.00%
Net Working Capital to Revenue	0.00%	14,986.44%	1,690.79%	1,801.37%	946.76%	181.71%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($3.58)	($3.86)	($3.08)	($2.57)	($2.01)	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	167.74M	113.15M	80.63M	74.19M	73.38M	0.00	0.00
Adjusted Diluted Earnings per Share	($3.58)	($3.86)	($3.08)	($2.57)	($2.01)	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	167.74M	113.15M	80.63M	74.19M	73.38M	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	($2.57)	($2.01)	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	185.91M	164.69M	90.49M	72.81M	54.87M	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-483	-341	-181	-132	-77	-38	-28
Normalized NOPAT Margin	0.00%	-2,944.99%	-511.01%	-447.79%	-180.28%	-75.71%	-140.00%
Pre Tax Income Margin	0.00%	-3,798.71%	-704.14%	-636.58%	-252.50%	-103.99%	-207.24%
Debt Service Ratios	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	-1,559.11	-510.57	-365.95
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	-1,091.38	-357.40	-243.36
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	-1,600.42	-533.14	-378.87
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	-1,132.69	-379.97	-256.29
Payout Ratios	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Revolution Medicines' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	-100.00%	-100.00%	-94.62%	-100.00%	-58.05%	-23.06%	45.79%	204.81%
EBITDA Growth	-60.55%	-21.51%	-44.28%	-45.54%	-99.79%	-225.38%	-67.75%	-87.31%	-28.82%	-15.22%	-48.98%
EBIT Growth	-70.53%	-23.29%	-42.34%	-42.21%	-85.96%	-212.97%	-61.04%	-75.23%	-21.05%	-8.80%	-43.96%
NOPAT Growth	-70.92%	-20.18%	-42.57%	-43.98%	-87.42%	-212.64%	-61.04%	-75.23%	-21.05%	-8.80%	-43.96%
Net Income Growth	-83.97%	-20.45%	-44.13%	-35.54%	-70.35%	-205.18%	-47.87%	-60.56%	-11.23%	-0.49%	-38.51%
EPS Growth	-61.43%	8.13%	5.05%	11.96%	2.78%	-115.79%	-13.79%	-12.20%	12.20%	20.83%	-20.83%
Operating Cash Flow Growth	-21.10%	-14.70%	-29.77%	-90.95%	-157.34%	-95.12%	-94.25%	-20.47%	-13.11%	-57.36%	-41.40%
Free Cash Flow Firm Growth	-23.09%	-161.24%	-37.36%	-255.57%	-137.75%	-7.18%	-66.83%	8.15%	-20.17%	-92.29%	-81.19%
Invested Capital Growth	-211.85%	9.96%	-30.66%	0.00%	2.72%	-166.50%	-8.12%	0.00%	-33.79%	57.74%	-10.64%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-100.00%	0.00%	-100.00%	-45.48%	-49.14%	310.97%	-63.19%
EBITDA Q/Q Growth	-7.41%	-24.94%	-11.87%	-6.95%	18.04%	-48.35%	-12.85%	-46.82%	-32.38%	23.52%	-26.01%
EBIT Q/Q Growth	-7.29%	-26.63%	-13.39%	-10.70%	22.35%	-46.19%	-13.28%	-44.76%	-30.55%	24.78%	-23.26%
NOPAT Q/Q Growth	-11.30%	-23.10%	-12.17%	-11.21%	21.74%	-46.03%	-13.28%	-44.76%	-30.55%	24.78%	-23.26%
Net Income Q/Q Growth	-9.69%	-24.49%	-17.30%	-14.85%	28.19%	-48.97%	-10.31%	-44.35%	-28.65%	27.82%	-19.78%
EPS Q/Q Growth	0.00%	-20.21%	-16.05%	-15.71%	43.09%	-24.24%	-7.61%	-27.78%	-26.32%	34.48%	-6.10%
Operating Cash Flow Q/Q Growth	-40.60%	-6.04%	-1.76%	20.18%	-33.18%	-19.97%	-49.73%	-7.58%	-0.98%	-19.43%	7.14%
Free Cash Flow Firm Q/Q Growth	20.77%	-33.34%	16.13%	-38.92%	-68.16%	29.89%	-117.11%	7.11%	24.19%	-9.12%	-19.54%
Invested Capital Q/Q Growth	-1.78%	-243.23%	-40.20%	28.30%	181.94%	-210.30%	0.00%	-100.00%	-46.96%	52.41%	-29.41%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	100.00%	0.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-25,241.64%	0.00%	-2,925.60%	-1,086.41%	-417.35%	-2,242.58%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-24,256.47%	0.00%	-2,845.11%	-1,071.53%	-417.40%	-2,280.48%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-24,281.81%	0.00%	-2,845.11%	-1,071.53%	-417.40%	-2,280.48%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-21,770.49%	0.00%	-2,570.55%	-970.89%	-383.79%	-2,185.01%
Tax Burden Percent	100.00%	99.61%	100.00%	100.00%	100.00%	100.21%	96.56%	100.00%	100.00%	99.77%	99.60%
Interest Burden Percent	89.55%	87.93%	89.09%	86.11%	83.00%	89.47%	91.12%	90.35%	90.61%	92.16%	96.20%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	-29,163.89%	0.00%	0.00%	-931.63%	-314.40%	-1,771.53%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	-29,161.04%	0.00%	0.00%	-929.47%	-312.33%	-1,768.41%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	29,004.47%	0.00%	0.00%	895.86%	296.38%	1,693.42%
Return on Equity (ROE)	-36.68%	-29.33%	0.00%	0.00%	0.00%	-159.42%	0.00%	0.00%	-35.78%	-18.02%	-78.11%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-2,189.54%	-3,189.47%	-1,791.43%	0.00%	-999.41%	0.00%	-668.28%	-594.68%	-623.34%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	-195.70%	0.00%	0.00%	-40.60%	-19.06%	-90.72%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	-175.46%	0.00%	0.00%	-36.79%	-17.52%	-86.93%
Return on Common Equity (ROCE)	-36.68%	-29.33%	0.00%	0.00%	0.00%	-159.42%	0.00%	0.00%	-35.78%	-18.02%	-78.11%
Return on Equity Simple (ROE_SIMPLE)	-33.56%	0.00%	-36.20%	-32.07%	-28.07%	0.00%	-39.14%	0.00%	-27.46%	0.00%	-36.46%
Net Operating Profit after Tax (NOPAT)	-169	-151	-123	-110	-99	-126	-86	-76	-53	-40	-54
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-16,979.53%	0.00%	-1,991.58%	-750.07%	-292.18%	-1,596.34%
Net Nonoperating Expense Percent (NNEP)	-2.36%	-2.08%	-2.82%	-2.97%	-1.33%	-2.85%	-3.02%	0.00%	-2.17%	-2.07%	-3.13%
Return On Investment Capital (ROIC_SIMPLE)	-8.11%	-6.68%	-	-	-	-6.90%	-	-	-	-5.88%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	4,345.55%	0.00%	382.85%	188.54%	70.65%	310.91%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	20,010.92%	0.00%	2,562.26%	982.99%	446.75%	2,069.58%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	24,356.47%	0.00%	2,945.11%	1,171.53%	517.40%	2,380.48%
Earnings before Interest and Taxes (EBIT)	-238	-222	-175	-155	-140	-180	-123	-109	-75	-58	-77
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-244	-228	-182	-163	-152	-187	-126	-112	-76	-58	-75
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.16	3.25	4.84	3.96	2.05	1.72	3.61	0.00	2.11	3.09	2.54
Price to Tangible Book Value (P/TBV)	3.28	3.35	5.07	4.14	2.14	1.79	3.95	0.00	2.28	3.46	2.85
Price to Revenue (P/Rev)	0.00	0.00	10,209.19	8,629.54	773.38	271.36	122.69	101.62	58.90	59.78	55.70
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	358.18	171.06	83.36	0.00	91.03	0.00	49.22	36.53	40.69
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	8,120.94	6,485.71	400.29	111.34	89.67	0.00	31.57	41.55	34.60
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.00	-1.01	-0.98	-0.98	-0.98	-0.99	-0.97	0.00	-0.96	-0.95	-0.96
Leverage Ratio	1.12	1.13	1.14	1.12	1.12	1.14	1.19	0.00	1.19	1.20	1.18
Compound Leverage Factor	1.01	0.99	1.02	0.96	0.93	1.02	1.09	0.00	1.07	1.11	1.14
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	13.25	14.84	22.55	19.92	11.45	7.96	11.48	0.00	7.84	9.50	6.69
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	13.46	14.20	14.24	15.42	18.45	13.06	9.64	0.00	11.81	10.65	9.21
Quick Ratio	13.26	13.97	13.98	15.10	18.18	12.89	9.51	0.00	11.68	10.48	9.01
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-122	-154	-116	-138	-99	-59	-84	-39	-42	-55	-50
Operating Cash Flow to CapEx	-5,953.31%	-11,316.69%	-3,705.09%	-5,342.52%	-5,069.78%	-5,203.41%	-3,964.38%	-5,998.30%	-3,548.98%	-2,148.40%	-1,467.72%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.01	0.03	0.00	0.04	0.05	0.04
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	3.91	9.38	0.00	8.43	6.67	5.03
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.03	0.03	0.21	0.56	1.28	0.00	2.03	2.34	2.19
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	93.41	38.89	0.00	43.29	54.69	72.61
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	93.41	38.89	0.00	43.29	54.69	72.61
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-25	-24	17	28	22	-27	24	0.00	21	40	26
Invested Capital Turnover	0.00	0.00	0.04	0.05	0.21	1.72	0.97	0.00	1.24	1.08	1.11
Increase / (Decrease) in Invested Capital	-46	2.67	-7.44	28	0.58	-67	-2.14	-37	-11	15	-3.14
Enterprise Value (EV)	4,471	5,069	6,026	4,812	1,828	1,289	2,209	0.00	1,051	1,470	1,074
Market Capitalization	6,574	7,358	7,575	6,403	3,531	3,142	3,022	2,844	1,960	2,115	1,729
Book Value per Share	$11.18	$13.47	$9.38	$9.81	$10.47	$16.67	$7.67	$0.00	$10.29	$7.72	$7.77
Tangible Book Value per Share	$10.80	$13.04	$8.95	$9.38	$10.04	$16.01	$7.01	$0.00	$9.48	$6.89	$6.93
Total Capital	2,078	2,265	1,566	1,619	1,725	1,826	837	0.00	931	685	681
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-2,103	-2,289	-1,549	-1,591	-1,704	-1,853	-813	0.00	-909	-645	-655
Capital Expenditures (CapEx)	3.27	1.22	3.52	2.40	3.17	2.32	2.54	1.12	1.76	2.88	3.53
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-127	-126	-81	-71	-68	-118	-74	0.00	-65	-47	-53
Debt-free Net Working Capital (DFNWC)	1,976	2,164	1,468	1,519	1,635	1,735	739	0.00	844	598	602
Net Working Capital (NWC)	1,976	2,164	1,468	1,519	1,635	1,735	739	0.00	844	598	602
Net Nonoperating Expense (NNE)	45	43	33	24	17	36	22	22	15	13	20
Net Nonoperating Obligations (NNO)	-2,103	-2,289	-1,549	-1,591	-1,704	-1,853	-813	0.00	-909	-645	-655
Total Depreciation and Amortization (D&A)	-6.10	-5.44	-6.72	-8.11	-12	-7.12	-3.00	-3.08	-1.04	0.01	1.27
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	-10,944.07%	-9,611.46%	-1,490.60%	-1,014.90%	-301.54%	0.00%	-196.69%	-132.11%	-171.27%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	197,880.86%	204,770.62%	35,818.64%	14,986.44%	3,000.11%	0.00%	2,536.31%	1,690.79%	1,938.41%
Net Working Capital to Revenue	0.00%	0.00%	197,880.86%	204,770.62%	35,818.64%	14,986.44%	3,000.11%	0.00%	2,536.31%	1,690.79%	1,938.41%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.13)	($1.13)	($0.94)	($0.81)	($0.70)	($1.23)	($0.99)	$0.00	$0.00	($0.57)	($0.87)
Adjusted Weighted Average Basic Shares Outstanding	188.15M	167.74M	166.84M	165.14M	164.73M	113.15M	109.23M	0.00	0.00	80.63M	84.69M
Adjusted Diluted Earnings per Share	($1.13)	($1.13)	($0.94)	($0.81)	($0.70)	($1.23)	($0.99)	$0.00	$0.00	($0.57)	($0.87)
Adjusted Weighted Average Diluted Shares Outstanding	188.15M	167.74M	166.84M	165.14M	164.73M	113.15M	109.23M	0.00	0.00	80.63M	84.69M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	186.27M	185.91M	168.22M	167.04M	164.99M	164.69M	109.56M	0.00	0.00	90.49M	88.79M
Normalized Net Operating Profit after Tax (NOPAT)	-169	-151	-123	-110	-99	-126	-86	-76	-53	-40	-54
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-16,979.53%	0.00%	-1,991.58%	-750.07%	-292.18%	-1,596.34%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-21,724.26%	0.00%	-2,570.55%	-970.89%	-384.68%	-2,193.86%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Revolution Medicines' Financials

When does Revolution Medicines's financial year end?

According to the most recent income statement we have on file, Revolution Medicines' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Revolution Medicines' net income changed over the last 6 years?

Revolution Medicines' net income appears to be on an upward trend, with a most recent value of -$600.09 million in 2024, rising from -$41.79 million in 2018. The previous period was -$436.37 million in 2023. View Revolution Medicines' forecast to see where analysts expect Revolution Medicines to go next.

What is Revolution Medicines's operating income?

Revolution Medicines's total operating income in 2024 was -$689.52 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $689.52 million

How has Revolution Medicines revenue changed over the last 6 years?

Over the last 6 years, Revolution Medicines' total revenue changed from $20.17 million in 2018 to $0.00 in 2024, a change of -100.0%.

How much debt does Revolution Medicines have?

Revolution Medicines' total liabilities were at $293.10 million at the end of 2024, a 24.5% increase from 2023, and a 331.1% increase since 2019.

How much cash does Revolution Medicines have?

In the past 5 years, Revolution Medicines' cash and equivalents has ranged from $16.66 million in 2019 to $696.15 million in 2023, and is currently $543.06 million as of their latest financial filing in 2024.

How has Revolution Medicines' book value per share changed over the last 6 years?

Over the last 6 years, Revolution Medicines' book value per share changed from 0.00 in 2018 to 13.47 in 2024, a change of 1,346.6%.

Related Companies

This page (NASDAQ:RVMD) was last updated on 5/31/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Revolution Medicines (RVMD) Financials

Frequently Asked Questions About Revolution Medicines' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Revolution Medicines (RVMD) Financials

Annual Income Statements for Revolution Medicines

Quarterly Income Statements for Revolution Medicines

Annual Cash Flow Statements for Revolution Medicines

Quarterly Cash Flow Statements for Revolution Medicines

Annual Balance Sheets for Revolution Medicines

Quarterly Balance Sheets for Revolution Medicines

Annual Metrics And Ratios for Revolution Medicines

Quarterly Metrics And Ratios for Revolution Medicines

Frequently Asked Questions About Revolution Medicines' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools